On Aug. 5, 2025, the Department of Health and Human Services canceled 22 federally funded mRNA vaccine development projects, a portfolio the article reports was worth roughly $500 million. The decision, announced by Health Secretary Robert F. Kennedy Jr., cited concerns about platform safety and effectiveness against upper respiratory infections such as Covid and influenza. One year later, the Food and Drug Administration approved mFlusiva, described in the source as the first mRNA seasonal influenza vaccine licensed in the United States.
Moderna reported Phase 3 results from a trial that enrolled 40,805 adults across 11 countries. The vaccine now known as mFlusiva outperformed a licensed standard-dose influenza vaccine by 26.6%, and the benefit extended to patients older than 65, according to the source. The FDA’s advisory committee voted unanimously that the benefits outweigh risks for adults 50–64 and again unanimously for adults 65 and older. The source emphasizes these findings as contradicting the administration’s claim that mRNA vaccines fail to protect effectively against influenza.
The source recounts that on Feb. 3 the FDA initially refused to review Moderna’s application for the mFlusiva license. The refusal letter was signed by the center director and objected solely to Moderna’s use of a standard-dose comparator rather than the high-dose influenza vaccine recommended for older adults. The article notes that this criterion does not appear in the agency’s influenza guidance and that the vaccine center had previously told Moderna that a standard-dose comparator was acceptable. Regulators in Europe, Canada, and Australia had accepted the identical application.
Fifteen days later, after one meeting and public outcry, the FDA reversed itself, agreed to review the submission, and set a decision date. The source stresses that nothing about the underlying evidence changed during that interval and characterizes the reversal as political rather than scientific.
The source highlights additional results that arrived after the HHS cancellations. It reports five-year data from an individualized mRNA therapy administered with pembrolizumab after surgery for high-risk melanoma; the combination reportedly reduced the risk of recurrence or death by 49% and the risk of distant metastasis by 59% at five years. The piece also cites a Memorial Sloan Kettering Phase 1 report in pancreatic cancer patients: among those whose immune systems responded to an individualized mRNA vaccine, nearly 90% were alive as long as six years after their final dose. The author notes that the pancreatic result comes from a small Phase 1 study and requires larger randomized trials for confirmation — precisely the sort of research the source says HHS cut.
The source points to a high-profile case in which a child referred to as KJ became the first person treated with a gene-editing therapy tailored to his mutation. The editor used to correct his DNA reached the liver as messenger RNA inside a lipid nanoparticle, the same delivery chemistry referenced in the administration’s canceled programs. The article emphasizes that half the infants born with KJ’s disorder historically do not reach their first birthday and that the treated child is walking and talking. It also cites an FDA proposal for a new pathway to speed therapies for children with ultra-rare diseases that would rely on the platform the secretary had defunded.
Despite the federal cancellations, the source reports that private capital and foreign governments continue to invest in mRNA science. The article warns that an increasing share of the world’s programs now originates in China and frames the U.S. decision as stepping away from a platform it invented. The author stresses that these trends risk shifting future medicine development away from the United States.
The source offers a clear policy fix: Congress should restore the canceled contracts and require that any decision to fund or defund an entire medical platform undergo scientific review rather than being announced by press release. The author argues that the secretary himself promised “gold-standard science” and that the evidence now exists in large clinical trials, cancer survival data, and the rare-disease treatment highlighted in the article.
The article concludes that the scientific record since the HHS cancellations undermines the rationale provided for halting federal mRNA investment. It maintains that the available evidence — including a 40,805-person Phase 3 influenza trial, multi-year cancer trial outcomes, and a treated child with a rare genetic disorder — contradicts the administration’s claims about the platform’s risks and effectiveness. The author warns that as long as the administration refuses to consider this evidence, Americans will be less healthy and the development of life-saving medicines will increasingly occur elsewhere.